AUTHORS
Arnon Nagler I, MD, Thibeault Ferhat Berland, PhD2, Francis Ayuk3, Igor Wolfgang Blau4, Tobias Gedde-Dahl5, Thomas Schroeder6, Matthias Eder7, Eva Wagner Drouet8, Vesa Lindström9, Francesca Kinsella, PhD10, Henrik Sengeloev11, Ibrahim Yakoub-Agha12, Jan Vydra13, Regis Peffault De Latour, MD, PhD14, Anna Grassi, MD15, Peter Pal Remenyi16, Ali Bazarbachi17, Bipin Savani, MD18, Mohamad Mohty, MD, PhD19, Fabio Ciceri20, Jaime Sanz, MD, PhD21, Eolia Brissot22
AFFILIATIONS
1 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel, Tel Hashomer, Israel
2 EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Sorbonne University, Paris, France, Paris, France
3 University Hospital Eppendorf, Hamburg, Germany, Hamburg, Germany
4 Medizinische Klinik m. S. Hämatologie, Onkologie und Tumorimmunologie, Berlin, Germany, Berlin, Germany
5 Oslo University Hospital, Rikshospitalet, Oslo, Finland, Oslo, Finland
6 University Hospital, Essen, Germany, Essen, Germany
7 Hannover Medical School, Hannover, Germany, Hannover, Germany
8 University Medical Center, Mainz, Germany, Mainz, Germany
9 HUCH Comprehensive Cancer Center, University of Turku, Finland, Turku, Finland
10 Birmingham Centre for Cellular Therapy and Transplant (BCCTT), Birmingham, UK, Birmingham, United Kingdom
11 Department of Hematology L, Rigshospitalet, Copenhagen, Denmark, Copenhagen, Denmark
12 CHU de Lille, Univ Lille, INSERM U1286, Infinite, 59000 Lille, France, Lille, France
13 Institute of Hematology and Blood Transfusion, Prague, Czech Republic, Prague, Czech Republic
14 BMT unit, Assistance Publique Hôpitaux de Paris, Université Paris Cité, Saint-Louis Hospital, BMT Unit, Paris, France, Paris, France
15 ASST Papa Giovanni XXIII, Bergamo, Italy, Bergamo, Italy
16 Del-pesti Centrumkorhaz, DPC Hospital Budapest, Hungary, Budapest, Hungary
17 Hematology-Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon, Beirut, Lebanon
18 Division of Hematology/ Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Nashville, United States
19 Sorbonne University, Department of Haematology, Saint Antoine Hospital; INSERM UMR 938, Paris, France, Paris, France
20 Ospedale San Raffaele, Haematology and BMT, Milano, Italy, Milano, Italy
21 Hospital Universitari i Politècnic La Fe, Valencia Departament de Medicina Universitat de Valencia, Spain, Valencia, Spain
22 Service d'Hématologie clinique et Thérapie cellulaire, Hôpital Saint-Antoine, APHP, Paris, France, Paris, France
ABSTRACT
Background:
The interval from diagnosis to transplantation (HSCT) is a determinant of transplant outcomes. We used the database of the ALWP / EBMT to evaluate the impact of time from diagnosis to transplantation on HSCT outcomes in adult patients (pts) with high risk acute leukemia (AL, AML and ALL), in CR1, undergoing HSCT between 2013 and 2023.
Methods: Donors were matched (10/10) or mismatched (9/10; MMUD) unrelated. The diagnosis to transplant interval was categorized as <123, 124–156, 157–203, and >203 days(d) for AML, and <154, 155–186, 187–238, and >238 d for ALL. MVA, adjusting for potential confounders, used Cox proportional hazards models for the main transplant outcomes.
Results: A total of 14,065 AML and 3,851 ALL pts were included. Among AML pts, 3,565 (25.3%) underwent HSCT <123 d of diagnosis, 3,495 between 124–156 d, 3,495 between 157–203 d, and 3,510 >203 d; the corresponding numbers for ALL were 987 (25.6%), 938, 972, and 954, respectively. Median follow-up was 4.0 years for both AML and ALL. Compared with AML pts transplanted >203 d after diagnosis, those transplanted <123 d underwent HSCT in an earlier calendar year (median 2018 vs 2019; both Q1–Q3, 2015–2021; P=0.003), were younger (57.5 vs 58.4 y; P<0.001), more frequently CMV seronegative (37.7% vs 30.1%; P<0.001), had KPS <90 more frequently (28.8% vs 19.5%; P<0.001), and more often had adverse-risk cytogenetics (29.7% vs 17.1%; P<0.001). They were less likely to receive an MMUD graft (16.4% vs 25.0%; P<0.001) and more likely to receive PB graft (95.7% vs 94.4%; P=0.004), MAC (51.9% vs 48.1%; P<0.001), and ATG for GVHD prophylaxis (73.1% vs 64.8%; P<0.001). As for ALL, pts undergoing HSCT <154 d of diagnosis were transplanted in a similar calendar year, were younger (P<0.032), more often with T-ALL (P<0.001), and were more frequently CMV seronegative (P<0.001) than those undergoing HSCT >238 d from diagnosis. They were less likely to receive an MMUD graft(P<0.001), and more likely to receive MAC (P<0.010) and ATG (P<0.002) as GVHD prophylaxis. In the MVA, AML pts undergoing HSCT <123 d of diagnosis had a lower risk of RI (HR 0.82, 95% CI 0.72–0.94; P=0.004), better GRFS (HR 0.87, 95% CI 0.79–0.96; P=0.006), and a lower incidence of severe aGVHD (HR 0.76, 95% CI 0.61–0.94; P=0.011) than those transplanted >203 d after diagnosis. OS, LFS, NRM, all grade aGVHD, total/extensive cGVHD, and neutrophil and platelet engraftment did not differ. No significant differences in transplant outcomes were observed between pts transplanted <123 d and those transplanted 124–156 or 157–203 d after diagnosis, except for better GRFS vs the 157–203 d group (HR 0.87, 95% CI 0.79–0.95; P=0.003). Similarly, in ALL, the diagnosis to transplant interval did not affect aGVHD or cGVHD, except for a lower incidence of all grade aGVHD in pts transplanted <154 d versus >238 d after diagnosis (HR 0.75, 95% CI 0.62–0.90; P=0.003). Pts transplanted <154 d had faster neutrophil engraftment (HR 0.89, 95% CI 0.80–1.00; P=0.043), with no difference in platelet engraftment. Compared with pts transplanted >238 d after diagnosis, they had significantly better OS (HR 1.19, 95% CI 1.00–1.41; P=0.041) and lower NRM (HR 1.30, 95% CI 1.03–1.65; P=0.026), with no differences in other outcomes. Likewise, no significant differences were observed between pts transplanted <154 d and those transplanted 155–186 d after diagnosis. However, compared with the 187–238 d group, pts transplanted <154 d had better LFS (HR 0.82, 95% CI 0.70–0.95; P=0.011), better GRFS (HR 0.83, 95% CI 0.72–0.95; P=0.001), and lower RI (HR 0.70, 95% CI 0.56–0.86; P=0.001).
Other independent prognostic factors for one or more transplant outcomes in both AML and ALL were cytogenetic risk, patient age, KPS, female donor to male recipient combination, year of transplantation, donor type, and conditioning regimen. Donor age and graft source were predictive only in AML.
Conclusions: In this retrospective analysis of pts with AL undergoing HSCT in CR1, a shorter diagnosis to transplant interval was associated with improved outcomes. AML pts transplanted <123 days had lower RI and severe aGVHD, with better GRFS. In ALL, transplantation <154 days was associated with lower NRM and cGVHD, faster neutrophil engraftment, and improved OS. Unlike disease, patient, donor, and transplant related prognostic factors, HSCT timing is a potentially modifiable factor that may be optimized through earlier referral to HSCT.
DISCLOSURES
Arnon Nagler I, MD: Micro CRISPR Pvt. Ltd - Consultancy (Includes expert testimony)